Together we are beating cancer

Donate now

Drug discovery and development

Showing 12 out of 69 results
Antibody

Follow Sophia Karagiannis and James Spicer on an immunological adventure as they develop a ground-breaking new class of drug... Follow Sophia Karagiannis and James Spicer on an immunological adventure as they develop a ground-breaking new class of drug...

by Cancer Research UK | In depth | 12 December 2023

12 December 2023

Breast magnetic resonance image, or MRI. The bright white dot in the larger images is stage one breast cancer.

New research from the ICR is showing us how additional measurements taken by MRI could speed up the development of new drugs that could make chemotherapies more effective New research from the ICR is showing us how additional measurements taken by MRI could speed up the development of new drugs that could make chemotherapies more effective

by Jacob Smith | Analysis | 9 May 2023

9 May 2023

Bowel cancer cells under the microscope

FOCUS4 was a large-scale trial investigating new treatments in people with advanced or metastatic colorectal cancer. Running it may not have been without its challenges, but the learnings it provided us with are invaluable if we're to run trials like it again.  FOCUS4 was a large-scale trial investigating new treatments in people with advanced or metastatic colorectal cancer. Running it may not have been without its challenges, but the learnings it provided us with are invaluable if we're to run trials like it again. 

by Jacob Smith | In depth | 25 April 2023

25 April 2023

The Antibody Alliance Laboratory – a collaboration between Cancer Research UK and AstraZeneca – combines academic rigour with agile bioengineering to push forward antibody discovery projects... The Antibody Alliance Laboratory – a collaboration between Cancer Research UK and AstraZeneca – combines academic rigour with agile bioengineering to push forward antibody discovery projects...

by Cancer Research UK | In depth | 15 December 2022

15 December 2022

T cell

Researchers in Southampton have found a way to improve the effectiveness of immunotherapy in cancers that are resistant by repurposing existing drugs Researchers in Southampton have found a way to improve the effectiveness of immunotherapy in cancers that are resistant by repurposing existing drugs

by Jacob Smith | Analysis | 11 November 2022

11 November 2022

A photo of Katie Currie with her mum and sister

In an unusual turn of events, the results of a clinical trial for mitoxantrone turned out to be so effective that the randomisation of the trial was halted early.  In an unusual turn of events, the results of a clinical trial for mitoxantrone turned out to be so effective that the randomisation of the trial was halted early. 

by Lilly Matson | Analysis | 16 September 2022

16 September 2022

Researchers at work in a Cancer Research UK laboratory

You may not know that as well as funding cancer research, we also work with industry and academia to develop promising ideas and turn them into real benefit for patients. Find out about Cancer Research Horizons. You may not know that as well as funding cancer research, we also work with industry and academia to develop promising ideas and turn them into real benefit for patients. Find out about Cancer Research Horizons.

by Lilly Matson | Analysis | 26 April 2022

26 April 2022

Forty years ago, hints of a new component of the immune system caused a stir. Here, we chart the story of gamma delta T cells from discovery to clinical trials... Forty years ago, hints of a new component of the immune system caused a stir. Here, we chart the story of gamma delta T cells from discovery to clinical trials...

by Cancer Research UK | In depth | 18 March 2022

18 March 2022

A photograph of a lab at the Imperial Cancer Research Fund in the 1960's.
  • Health & Medicine
  • Science & Technology

Diving into our role in 50 top cancer drugs

To mark 20 years since the merger of the Cancer Research Campaign and the Imperial Cancer Research Fund, we’ve delved into the research of the charities' that led to many of the drugs in use today. To mark 20 years since the merger of the Cancer Research Campaign and the Imperial Cancer Research Fund, we’ve delved into the research of the charities' that led to many of the drugs in use today.

by Catherine Pickworth | In depth | 9 February 2022

9 February 2022

Pioneering therapeutics targeting the damage repair mechanism of DNA polymerase theta in a range of cancers have entered human trials - we tell the story from discovery to translation. Pioneering therapeutics targeting the damage repair mechanism of DNA polymerase theta in a range of cancers have entered human trials - we tell the story from discovery to translation.

by Cancer Research UK | In depth | 5 November 2021

5 November 2021

The logo of our podcast, That Cancer Conversation

From groundbreaking rare cancer research to ending up on Forbes 30 under 30, we chat to Sigourney Bell about her work in the lab and her global organisation, Black in Cancer. From groundbreaking rare cancer research to ending up on Forbes 30 under 30, we chat to Sigourney Bell about her work in the lab and her global organisation, Black in Cancer.

by Cancer Research UK | Podcast | 8 October 2021

8 October 2021

This entry is part 3 of 13 in the series That Cancer Conversation